• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Vaccines, Blood & Biologics

  • Print
  • Share
  • E-mail

Section Contents Menu


Record of Telephone Conversation - May 1, 2009-1 - Prevnar 13

System Info - 113387  SMITH, MICHAEL J  10-Dec-2009 10:29:10  SMITHM


Submission Type: Original Application   Submission ID:  125324/0    Office: OVRR  

Pneumococcal 13-valent Conjugate Vaccine (Diphtheria CRM197 Protein)

Wyeth Pharmaceuticals Inc.          

Telecon Date/Time:  01-MAY-2009 02:30 PM              Initiated by FDA?  Yes
Telephone Number:    

Communication Categorie(s):
Information Request


Telecon Summary:
RE: Email IR for 5 SOPs

FDA Participants:   Mike Smith and Julie Vaillancourt

Non-FDA Participants:    Jack Love and Carmel Devlin

Trans-BLA Group: No

Related STNs:  None

Related PMCs:  None

Telecon Body:
From:                     Smith, Michael (CBER) 
Sent:                      Friday, May 01, 2009 2:31 PM
To:                          'LOVEJ@wyeth.com'; 'DEVLINC@wyeth.com'
Cc:                          Vaillancourt, Julienne
Subject:                RE: Request for additional documents for BLA 125324

Jack and Carmel,

    I have an additional list of documents to request, please submit these documents to the BLA as an amendment.

1. Detailed SOPs for all serotype Pneumococcal Activation Processes.

2. Detailed SOPs for ------(b)(4)---- and Reconstitution for all serotypes.

3. Detailed SOPs for Conjugation Reaction for all serotypes.

4. Detailed SOPs for -----------(b)(4)------ impurity removal for all serotypes.

5. Detailed SOPs for ------------(b)(4)------ impurity removal for all serotypes.

Thank you,


End of email.


Contact FDA

(800) 835-4709
(240) 402-8010
Consumer Affairs Branch (CBER)

Division of Communication and Consumer Affairs

Office of Communication, Outreach and Development

Food and Drug Administration

10903 New Hampshire Avenue

Building 71 Room 3103

Silver Spring, MD 20993-0002